Vaxart, Inc. (NASDAQ:VXRT) reported its first-quarter financial results after the bell Monday. Here's a look at the details.  The Details: Vaxart reported quarterly losses of 14 cents per share, inline with the analyst consensus estimate. Quarterly sales clocked in at $2.181 million, beating the analyst consensus estimate of $800,000 by 172.63% and representing a 223.11% increase over sales of $675,000 from the same period last year. The company said it is preparing for a 10,000-subject, Phase 2b clinical study evaluating its oral pill XBB COVID-19 vaccine candidate against an approved mRNA vaccine comparator. The preparations are being supported by a ...